288 related articles for article (PubMed ID: 21062730)
21. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
Powles T; Thirwell C; Newsom-Davis T; Nelson M; Shah P; Cox S; Gazzard B; Bower M
Br J Cancer; 2003 Aug; 89(3):457-9. PubMed ID: 12888811
[TBL] [Abstract][Full Text] [Related]
22. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
[TBL] [Abstract][Full Text] [Related]
23. Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009.
Ferraresi A; Calabresi A; Castelli F; Vavassori A; Castelnuovo F; Scalzini A; Torti C; Quiros-Roldan E
Int J STD AIDS; 2012 Oct; 23(10):753-5. PubMed ID: 23104752
[TBL] [Abstract][Full Text] [Related]
24. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features of lung cancer HIV-infected patients].
Kato T; Ieki R; Saito E; Ot T; Yuasa K; Iguchi M; Okamura T; Shibuya M; Ajisawa A
Nihon Kokyuki Gakkai Zasshi; 2007 Sep; 45(9):661-6. PubMed ID: 17929466
[TBL] [Abstract][Full Text] [Related]
26. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
27. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
28. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
29. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
Blazy A; Hennequin C; Gornet JM; Furco A; Gérard L; Lémann M; Maylin C
Dis Colon Rectum; 2005 Jun; 48(6):1176-81. PubMed ID: 15906137
[TBL] [Abstract][Full Text] [Related]
30. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
[TBL] [Abstract][Full Text] [Related]
31. Cancers not associated with immunodeficiency in HIV infected persons.
Gunthel CJ; Northfelt DW
Oncology (Williston Park); 1994 Jul; 8(7):59-64; discussion 64, 67-8, 70. PubMed ID: 7917842
[TBL] [Abstract][Full Text] [Related]
32. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
33. Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.
Blair JM; McNaghten AD; Frazier EL; Skarbinski J; Huang P; Heffelfinger JD
MMWR Surveill Summ; 2011 Sep; 60(11):1-20. PubMed ID: 21881551
[TBL] [Abstract][Full Text] [Related]
34. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
35. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
Dheda K; Lampe FC; Johnson MA; Lipman MC
J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
[TBL] [Abstract][Full Text] [Related]
36. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.
Castillo JJ; Furman M; Beltrán BE; Bibas M; Bower M; Chen W; Díez-Martín JL; Liu JJ; Miranda RN; Montoto S; Nanaji NM; Navarro JT; Seegmiller AC; Vose JM
Cancer; 2012 Nov; 118(21):5270-7. PubMed ID: 22510767
[TBL] [Abstract][Full Text] [Related]
37. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
[TBL] [Abstract][Full Text] [Related]
38. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
39. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study.
Rengan R; Mitra N; Liao K; Armstrong K; Vachani A
Lancet Oncol; 2012 Dec; 13(12):1203-9. PubMed ID: 23164952
[TBL] [Abstract][Full Text] [Related]
40. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
